Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study

Ned Sacktor, G. Schifitto, M. P. McDermott, K. Marder, Justin Charles McArthur, K. Kieburtz

Research output: Contribution to journalArticle

Abstract

The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.

Original languageEnglish (US)
Pages (from-to)233-235
Number of pages3
JournalNeurology
Volume54
Issue number1
StatePublished - Jan 11 2000

Fingerprint

Selegiline
Placebos
HIV
Cutaneous Administration
Psychomotor Performance
Controlled Clinical Trials
Safety
Cognitive Dysfunction

Keywords

  • Cognitive impairment
  • HIV
  • Selegiline

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sacktor, N., Schifitto, G., McDermott, M. P., Marder, K., McArthur, J. C., & Kieburtz, K. (2000). Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study. Neurology, 54(1), 233-235.

Transdermal selegiline in HIV-associated cognitive impairment : Pilot, placebo-controlled study. / Sacktor, Ned; Schifitto, G.; McDermott, M. P.; Marder, K.; McArthur, Justin Charles; Kieburtz, K.

In: Neurology, Vol. 54, No. 1, 11.01.2000, p. 233-235.

Research output: Contribution to journalArticle

Sacktor, N, Schifitto, G, McDermott, MP, Marder, K, McArthur, JC & Kieburtz, K 2000, 'Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study', Neurology, vol. 54, no. 1, pp. 233-235.
Sacktor, Ned ; Schifitto, G. ; McDermott, M. P. ; Marder, K. ; McArthur, Justin Charles ; Kieburtz, K. / Transdermal selegiline in HIV-associated cognitive impairment : Pilot, placebo-controlled study. In: Neurology. 2000 ; Vol. 54, No. 1. pp. 233-235.
@article{c400944a675e44e4995919e0cf72205f,
title = "Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study",
abstract = "The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.",
keywords = "Cognitive impairment, HIV, Selegiline",
author = "Ned Sacktor and G. Schifitto and McDermott, {M. P.} and K. Marder and McArthur, {Justin Charles} and K. Kieburtz",
year = "2000",
month = "1",
day = "11",
language = "English (US)",
volume = "54",
pages = "233--235",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Transdermal selegiline in HIV-associated cognitive impairment

T2 - Pilot, placebo-controlled study

AU - Sacktor, Ned

AU - Schifitto, G.

AU - McDermott, M. P.

AU - Marder, K.

AU - McArthur, Justin Charles

AU - Kieburtz, K.

PY - 2000/1/11

Y1 - 2000/1/11

N2 - The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.

AB - The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.

KW - Cognitive impairment

KW - HIV

KW - Selegiline

UR - http://www.scopus.com/inward/record.url?scp=0033958299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033958299&partnerID=8YFLogxK

M3 - Article

C2 - 10636157

AN - SCOPUS:0033958299

VL - 54

SP - 233

EP - 235

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -